GlassScriptPhysician profile
Brent R Gill
NPI 1851361976
$1,692.82
in general payments reported to CMS, 2019-2025
23 companies · $224 in 2025
The $224 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2020: $69.71 · 2021: $235 · 2022: $281 · 2023: $351 · 2024: $260 · 2025: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $835.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $834.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $327.03 | 2019-2024 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $258.14 | 2021-2025 | |
| Glaxosmithkline, LLC. | $221.65 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $165.64 | 2019-2025 | Xifaxan |
| Novo Nordisk INC | $163.95 | 2019-2025 | Ozempic, Rybelsus |
| Daiichi Sankyo INC. | $101.57 | 2019-2024 | Injectafer |
| Novartis Pharmaceuticals Corporation | $60.75 | 2021-2022 | |
| Eisai INC. | $52.99 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $45.48 | 2024-2025 | Airsupra, Breztri |
| Sunovion Pharmaceuticals INC. | $40.78 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.41 | 2021-2024 | |
| Ironwood Pharmaceuticals, INC | $32.16 | 2021-2024 | |
| Ani Pharmaceuticals, INC. | $28.82 | 2025 | Purified Cortrophin Gel |
| Pfizer INC. | $26.43 | 2022-2024 | |
| Medtronic, INC. | $18.88 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Masimo Corporation | $15.82 | 2023 | Set and Rainbow Set, Patient Safetynet System |
| Edwards Lifesciences Corporation | $15.62 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Lilly USA, LLC | $15.36 | 2024 | Jardiance |
| Alnylam Pharmaceuticals INC. | $13.08 | 2023 | Onpattro |
| Janssen Pharmaceuticals, INC | $12.71 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.23 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.21 | 2021 | |
| Allergan, INC. | $12.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brent Gill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.